Piperaquine

Piperaquine

Clinical data
ATC code	P01BF05 (WHO) (combination with artenimol), P01BX02 (WHO) (combination with arterolane)
Identifiers
IUPAC name 1,3-bis[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propane
CAS Number	4085-31-8 Y
PubChem (CID)	122262
ChemSpider	109031 N
UNII	A0HV2Q956Y N
ChEBI	CHEBI:91231 N
ChEMBL	CHEMBL303933 N
Chemical and physical data
Formula	C29H32Cl2N6
Molar mass	535.51 g/mol
3D model (Jmol)	Interactive image
SMILES C1CN(CCN1CCCN2CCN(CC2)C3=C4C=CC(=CC4=NC=C3)Cl)C5=C6C=CC(=CC6=NC=C5)Cl
InChI InChI=1S/C29H32Cl2N6/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29/h2-9,20-21H,1,10-19H2 N Key:UCRHFBCYFMIWHC-UHFFFAOYSA-N N
NY (what is this?)

Piperaquine is an antimalarial drug, a bisquinoline first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. Usage declined in the 1980s as piperaquine-resistant strains of P. falciparum arose and artemisinin-based antimalarials became available. However, Chinese scientists have been studying whether piperaquine can still be used therapeutically in combination with artemisinin.

Piperaquine is characterized by slow absorption and a long biological half-life, making it a good partner drug with artemisinin derivatives which are fast acting but have a short biological half-life.

The fixed-dose combination dihydroartemisinin-piperaquine (Eurartesim) was submitted for approval to the European Medicines Agency in 2009.